Literature DB >> 22923053

What is the role of sedating antidepressants, antipsychotics, and anticonvulsants in the management of insomnia?

Catherine McCall1, W Vaughn McCall.   

Abstract

Psychiatric medications such as antidepressants, antipsychotics, and anticonvulsants are commonly prescribed by physicians for the off-label use of improving sleep. Reasons for preferential prescription of these medications over FDA-approved insomnia drugs may include a desire to treat concurrent sleep problems and psychiatric illness with a single medication, and/or an attempt to avoid hypnotic drugs due to their publicized side effects. However, there have been few large studies demonstrating the efficacy and safety of most off-label medications prescribed to treat insomnia. In addition, many of these medications have significant known side effect profiles themselves. Here we review the pertinent research studies published in recent years on antidepressant, antipsychotic, and anticonvulsant medications frequently prescribed for sleep difficulties. Although there have been few large-scale studies for most of these medications, some may be appropriate in the treatment of sleep issues in specific well-defined populations.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22923053     DOI: 10.1007/s11920-012-0302-y

Source DB:  PubMed          Journal:  Curr Psychiatry Rep        ISSN: 1523-3812            Impact factor:   5.285


  68 in total

1.  Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalised anxiety disorder: an analysis of pooled data from three 8-week placebo-controlled studies.

Authors:  Dan J Stein; Borwin Bandelow; Charles Merideth; Bengt Olausson; Johan Szamosi; Hans Eriksson
Journal:  Hum Psychopharmacol       Date:  2011-12-06       Impact factor: 1.672

2.  Effect of the antidepressant Org 3770 on human sleep.

Authors:  G S Ruigt; B Kemp; C M Groenhout; H A Kamphuisen
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

3.  Efficacy and safety of zolpidem-MR: a double-blind, placebo-controlled study in adults with primary insomnia.

Authors:  Thomas Roth; Christina Soubrane; Laurence Titeux; James K Walsh
Journal:  Sleep Med       Date:  2006-07-03       Impact factor: 3.492

4.  Efficacy and safety of doxepin 3 and 6 mg in a 35-day sleep laboratory trial in adults with chronic primary insomnia.

Authors:  Andrew D Krystal; Alan Lankford; H Heith Durrence; Elizabeth Ludington; Philip Jochelson; Roberta Rogowski; Thomas Roth
Journal:  Sleep       Date:  2011-10-01       Impact factor: 5.849

5.  Case series of perimenopausal women with insomnia treated with mirtazapine followed by prolonged-release melatonin add-on and monotherapy.

Authors:  Zipora Dolev
Journal:  Arch Womens Ment Health       Date:  2011-02-12       Impact factor: 3.633

6.  Efficacy and safety of doxepin 6 mg in a four-week outpatient trial of elderly adults with chronic primary insomnia.

Authors:  Alan Lankford; Roberta Rogowski; Beal Essink; Elizabeth Ludington; H Heith Durrence; Thomas Roth
Journal:  Sleep Med       Date:  2011-12-24       Impact factor: 3.492

7.  A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia.

Authors:  Lesley M Arnold; I Jon Russell; E W Diri; W Rachel Duan; James P Young; Uma Sharma; Susan A Martin; Jeannette A Barrett; George Haig
Journal:  J Pain       Date:  2008-06-03       Impact factor: 5.820

8.  A double-blind trial of gabapentin versus lorazepam in the treatment of alcohol withdrawal.

Authors:  Hugh Myrick; Robert Malcolm; Patrick K Randall; Elizabeth Boyle; Raymond F Anton; Howard C Becker; Carrie L Randall
Journal:  Alcohol Clin Exp Res       Date:  2009-05-26       Impact factor: 3.455

9.  Sleep-promoting properties of quetiapine in healthy subjects.

Authors:  Stefan Cohrs; Andrea Rodenbeck; Zhenghua Guan; Kathrin Pohlmann; Wolfgang Jordan; Andreas Meier; Eckart Rüther
Journal:  Psychopharmacology (Berl)       Date:  2004-03-17       Impact factor: 4.530

10.  Mirtazapine, a sedating antidepressant, and improved driving safety in patients with major depressive disorder: a prospective, randomized trial of 28 patients.

Authors:  Jianhua Shen; Henry J Moller; Xuehua Wang; Sharon A Chung; Gilla K Shapiro; Xiuying Li; Colin M Shapiro
Journal:  J Clin Psychiatry       Date:  2009-01-13       Impact factor: 4.384

View more
  5 in total

Review 1.  Sleep Disturbances in Neurodevelopmental Disorders.

Authors:  Althea Robinson-Shelton; Beth A Malow
Journal:  Curr Psychiatry Rep       Date:  2016-01       Impact factor: 5.285

Review 2.  Sleep, insomnia, and depression.

Authors:  Dieter Riemann; Lukas B Krone; Katharina Wulff; Christoph Nissen
Journal:  Neuropsychopharmacology       Date:  2019-05-09       Impact factor: 7.853

Review 3.  Neurodevelopmental Disorders Commonly Presenting with Sleep Disturbances.

Authors:  Althea Robinson Shelton; Beth Malow
Journal:  Neurotherapeutics       Date:  2021-01-05       Impact factor: 7.620

Review 4.  At the intersection of sleep deficiency and opioid use: mechanisms and therapeutic opportunities.

Authors:  Mark K Greenwald; Tabitha E H Moses; Timothy A Roehrs
Journal:  Transl Res       Date:  2021-03-09       Impact factor: 10.171

5.  Antinociceptive and Antiallodynic Activity of Some 3-(3-Methylthiophen-2-yl)pyrrolidine-2,5-dione Derivatives in Mouse Models of Tonic and Neuropathic Pain.

Authors:  Anna Dziubina; Anna Rapacz; Anna Czopek; Małgorzata Góra; Jolanta Obniska; Krzysztof Kamiński
Journal:  Int J Mol Sci       Date:  2022-04-06       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.